Maxime Dely: Trends in Red Blood Cell Consumption in France
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“Trends in Red Blood Cell (RBC) consumption in France
- A steady decline over the past decade
Over the last ten years, a clear trend has emerged: overall RBC consumption in France has been steadily decreasing.
This evolution is largely driven by major advances in medical and surgical practices. Procedures are now more targeted and minimally invasive, with better anticipation of bleeding risks.
At the same time, transfusion best practices have evolved significantly: the goal is no longer to transfuse more, but to transfuse appropriately, avoiding unnecessary over-transfusion.
- Fewer standard RBC units, but more relevant transfusion strategies.
- A significant shift in the nature of transfusion needs
This overall decline does not mean that transfusion challenges are disappearing. On the contrary, the profile of needs is changing.
In France, a genetic disease remains highly prevalent: sickle cell disease.
These patients often require regular red blood cell exchange transfusions, frequently performed through erythrocytapheresis, and depend on RBC units with rare blood group phenotypes.
- A dual dynamic to consider
We are now facing a clear correlation: a decrease in standard RBC consumption, alongside an increase in demand for highly specific and rare RBC units.
- A direct impact on donor recruitment strategies
This shift is profoundly reshaping donor recruitment and communication strategies.
Where “standard” donor profiles were largely sufficient 10–15 years ago, there is now a growing need for targeted outreach, focused on donors with rare blood groups.
- Transfusion medicine is evolving.
- Blood donor recruitment must evolve with it.”
Find more posts featuring Maxime Dely on Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS